
MoonLake Immunotherapeutics: shareholders and insiders
Price
$11.07
November 20, 2026Market cap $942M
What Ploutos Investor adds for MoonLake Immunotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Jul 29, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$81M
4 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan14%
- The rest86%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $77M by 4 people
- 2025: no buys, sold $4.0M by 2 people
- 2026: no buys, sold $77M by 4 people
- Jul 27, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- Jul 22, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- Jul 21, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- Jul 20, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- Jul 15, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- Jul 10, 2026da Silva Jorge SantosChief Executive OfficerKind10b5-1
- Jul 9, 2026da Silva Jorge SantosChief Executive OfficerKind10b5-1
- Jul 1, 2026da Silva Jorge SantosChief Executive OfficerKind10b5-1
- Jun 22, 2026Matthias BodenstedtChief Financial OfficerKind10b5-1
- Jun 18, 2026Matthias BodenstedtChief Financial OfficerKind10b5-1
- Jun 17, 2026Matthias BodenstedtChief Financial OfficerKind10b5-1
- Jun 17, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- Jun 16, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- Jun 15, 2026Kristian ReichChief Scientific OfficerKind10b5-1
- May 11, 2026Matthias BodenstedtChief Financial OfficerKind10b5-1
- Apr 14, 2026Matthias BodenstedtChief Financial OfficerKind10b5-1
- Apr 13, 2026da Silva Jorge SantosChief Executive OfficerKind
- Apr 10, 2026da Silva Jorge SantosChief Executive OfficerKind
- Apr 10, 2026Matthias BodenstedtChief Financial OfficerKind10b5-1
- Apr 9, 2026Matthias BodenstedtChief Financial OfficerKind10b5-1
- Mar 31, 2026Mark N LampertKind
- Mar 31, 2026Mark N LampertKind
- Mar 31, 2026Mark N LampertKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 1,100 | $20.00 | $22.0K | Form 4 |
| Jul 22, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 2,448 | $20.00 | $49.0K | Form 4 |
| Jul 21, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 50.0K | $20.02 | $1.0M | Form 4 |
| Jul 20, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 43.7K | $20.09 | $877.9K | Form 4 |
| Jul 15, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 16.1K | $20.01 | $322.3K | Form 4 |
| Jul 10, 2026 | da Silva Jorge SantosChief Executive Officer | 10b5-1 | 68.3K | $20.02 | $1.4M | Form 4 |
| Jul 9, 2026 | da Silva Jorge SantosChief Executive Officer | 10b5-1 | 33.9K | $20.01 | $679.1K | Form 4 |
| Jul 1, 2026 | da Silva Jorge SantosChief Executive Officer | 10b5-1 | 47.8K | $20.03 | $956.9K | Form 4 |
| Jun 22, 2026 | Matthias BodenstedtChief Financial Officer | 10b5-1 | 39.1K | $22.04 | $862.2K | Form 4 |
| Jun 18, 2026 | Matthias BodenstedtChief Financial Officer | 10b5-1 | 2,794 | $19.60 | $54.8K | Form 4 |
| Jun 17, 2026 | Matthias BodenstedtChief Financial Officer | 10b5-1 | 15.1K | $19.68 | $296.8K | Form 4 |
| Jun 17, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 50.0K | $19.43 | $971.5K | Form 4 |
| Jun 16, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 50.0K | $18.70 | $935.0K | Form 4 |
| Jun 15, 2026 | Kristian ReichChief Scientific Officer | 10b5-1 | 50.0K | $18.89 | $944.5K | Form 4 |
| May 11, 2026 | Matthias BodenstedtChief Financial Officer | 10b5-1 | 13.7K | $20.02 | $273.3K | Form 4 |
| Apr 14, 2026 | Matthias BodenstedtChief Financial Officer | 10b5-1 | 2,426 | $19.56 | $47.5K | Form 4 |
| Apr 13, 2026 | da Silva Jorge SantosChief Executive Officer | 51.9K | $18.23 | $945.6K | Form 4 | |
| Apr 10, 2026 | da Silva Jorge SantosChief Executive Officer | 98.1K | $18.41 | $1.8M | Form 4 | |
| Apr 10, 2026 | Matthias BodenstedtChief Financial Officer | 10b5-1 | 1,925 | $19.51 | $37.6K | Form 4 |
| Apr 9, 2026 | Matthias BodenstedtChief Financial Officer | 10b5-1 | 85.9K | $18.94 | $1.6M | Form 4 |
| Mar 31, 2026 | Mark N Lampert | 248.5K | $16.79 | $4.2M | Form 4 | |
| Mar 31, 2026 | Mark N Lampert | 1.57M | $16.79 | $26M | Form 4 | |
| Mar 31, 2026 | Mark N Lampert | 1.93M | $16.79 | $32M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 17, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by MLTX's officers and directors from 2020 up to November 21, 2025, 6 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 1 more, back to 2020
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Biotechnology Value Fund L Pwith 10 more personsClass A ordinary share, par value $0.0001 per shareShare of class19.7%
- Deep Track Capital, LPwith 2 more personsClass A ordinary share, par value $0.0001 per shareShare of class9.74%
- T. Rowe Price Investment Management, Inc.Share of class5.30%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Biotechnology Value Fund L Pwith 10 more personsClass A ordinary share, par value $0.0001 per share | 19.7% | 16.00M | Jun 29, 20263 filings since Nov 10, 2025 | 13D/A | |
| Deep Track Capital, LPwith 2 more personsClass A ordinary share, par value $0.0001 per share | 9.74% | 8.00M | Aug 14, 20262 filings since Nov 12, 2025 | 13G/A | |
| T. Rowe Price Investment Management, Inc. | 5.30% | 4.28M | Aug 14, 2026 | 13G |
Fell to 5% or less (5)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Duquesne (Druckenmiller)In the quarter
- Point72 (Cohen)In the quarter
- D.E. ShawIn the quarter+3.6%
- Renaissance TechnologiesIn the quarter+167%
- Citadel Advisors (Griffin)In the quarter-14%
- Millennium Mgmt (Englander)In the quarter+141%
- AQR CapitalIn the quarter-8.9%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Duquesne (Druckenmiller) | 494.0K | $5.8M | 0.14% | |
| Point72 (Cohen) | – | – | 0.03% | |
| D.E. Shaw | 3.49M | +3.6% | $41M | 0.03% |
| Renaissance Technologies | 1.72M | +167% | $20M | 0.03% |
| Citadel Advisors (Griffin) | 1.71M | -14% | $20M | 0.01% |
| Millennium Mgmt (Englander) | 1.53M | +141% | $18M | 0.01% |
| AQR Capital | 326.8K | -8.9% | $3.8M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 9.20% of its shares outstanding were held short, -2.7% since the report before.
- Shares held short
- 7.83M
- 9.20%
- Since the report before8.05M on Sep 30, 2026
- -2.7%
- 4.1
- 1.92M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 49%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.64M
- Nov 15, 2023: Shares held short 7.32M
- Nov 30, 2023: Shares held short 7.83M
- Dec 15, 2023: Shares held short 7.51M
- Dec 29, 2023: Shares held short 6.91M
- Jan 12, 2024: Shares held short 6.89M
- Jan 31, 2024: Shares held short 6.67M
- Feb 15, 2024: Shares held short 6.61M
- Feb 29, 2024: Shares held short 6.94M
- Mar 15, 2024: Shares held short 7.00M
- Mar 28, 2024: Shares held short 7.65M
- Apr 15, 2024: Shares held short 7.26M
- Apr 30, 2024: Shares held short 6.93M
- May 15, 2024: Shares held short 7.28M
- May 31, 2024: Shares held short 7.88M
- Jun 14, 2024: Shares held short 7.82M
- Jun 28, 2024: Shares held short 7.83M
- Jul 15, 2024: Shares held short 7.91M
- Jul 31, 2024: Shares held short 7.77M
- Aug 15, 2024: Shares held short 7.76M
- Aug 30, 2024: Shares held short 7.94M
- Sep 13, 2024: Shares held short 7.77M
- Sep 30, 2024: Shares held short 7.97M
- Oct 15, 2024: Shares held short 8.15M
- Oct 31, 2024: Shares held short 8.06M
- Nov 15, 2024: Shares held short 8.00M
- Nov 29, 2024: Shares held short 8.00M
- Dec 13, 2024: Shares held short 8.04M
- Dec 31, 2024: Shares held short 8.08M
- Jan 15, 2025: Shares held short 7.80M
- Jan 31, 2025: Shares held short 7.68M
- Feb 14, 2025: Shares held short 8.05M
- Feb 28, 2025: Shares held short 7.44M
- Mar 14, 2025: Shares held short 7.24M
- Mar 31, 2025: Shares held short 6.35M
- Apr 15, 2025: Shares held short 6.63M
- Apr 30, 2025: Shares held short 6.10M
- May 15, 2025: Shares held short 6.04M
- May 30, 2025: Shares held short 6.31M
- Jun 13, 2025: Shares held short 6.12M
- Jun 30, 2025: Shares held short 6.07M
- Jul 15, 2025: Shares held short 6.34M
- Jul 31, 2025: Shares held short 6.13M
- Aug 15, 2025: Shares held short 5.37M
- Aug 29, 2025: Shares held short 5.18M
- Sep 15, 2025: Shares held short 4.95M
- Sep 30, 2025: Shares held short 5.77M
- Oct 15, 2025: Shares held short 4.89M
- Oct 31, 2025: Shares held short 4.91M
- Nov 14, 2025: Shares held short 3.86M
- Nov 28, 2025: Shares held short 4.27M
- Dec 15, 2025: Shares held short 4.89M
- Dec 31, 2025: Shares held short 5.78M
- Jan 15, 2026: Shares held short 7.18M
- Jan 30, 2026: Shares held short 7.02M
- Feb 13, 2026: Shares held short 7.27M
- Feb 27, 2026: Shares held short 7.04M
- Mar 13, 2026: Shares held short 7.31M
- Mar 31, 2026: Shares held short 7.76M
- Apr 15, 2026: Shares held short 6.65M
- Apr 30, 2026: Shares held short 6.32M
- May 15, 2026: Shares held short 5.47M
- May 29, 2026: Shares held short 5.57M
- Jun 15, 2026: Shares held short 5.32M
- Jun 30, 2026: Shares held short 6.56M
- Jul 15, 2026: Shares held short 6.33M
- Jul 31, 2026: Shares held short 5.72M
- Aug 14, 2026: Shares held short 6.82M
- Aug 31, 2026: Shares held short 7.14M
- Sep 15, 2026: Shares held short 8.95M
- Sep 30, 2026: Shares held short 8.05M
- Oct 15, 2026: Shares held short 7.83M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading51.6% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 51.6% of the shares in the reported trades were short sales, against 44.8% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 51.6%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 44.8%
- Change
- +6.8 pts
- Short sales a dayon average, of 529.8K shares
- 273.6K
- More than atof 3,666 US-listed companies, same days
- 54%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 46%
- Oct 15, 2026: Short sales 27%
- Oct 16, 2026: Short sales 53.2%
- Oct 19, 2026: Short sales 54.2%
- Oct 20, 2026: Short sales 43.1%
- Oct 21, 2026: Short sales 50.6%
- Oct 22, 2026: Short sales 43.2%
- Oct 23, 2026: Short sales 45.1%
- Oct 26, 2026: Short sales 49.7%
- Oct 27, 2026: Short sales 38.3%
- Oct 28, 2026: Short sales 42.8%
- Oct 29, 2026: Short sales 46%
- Oct 30, 2026: Short sales 38.4%
- Nov 2, 2026: Short sales 52.2%
- Nov 3, 2026: Short sales 53.8%
- Nov 4, 2026: Short sales 52.2%
- Nov 5, 2026: Short sales 56.6%
- Nov 6, 2026: Short sales 23%
- Nov 9, 2026: Short sales 39.1%
- Nov 10, 2026: Short sales 44.1%
- Nov 11, 2026: Short sales 35.9%
- Nov 12, 2026: Short sales 53.3%
- Nov 13, 2026: Short sales 71.2%
- Nov 16, 2026: Short sales 63.6%
- Nov 17, 2026: Short sales 51.3%
- Nov 18, 2026: Short sales 50.3%
- Nov 19, 2026: Short sales 64.5%
- Nov 20, 2026: Short sales 58.9%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- da Silva Jorge SantosChief Executive OfficerDirectly2.77M
- Kristian ReichChief Scientific OfficerDirectly2.75M
- Matthias BodenstedtChief Financial OfficerDirectly1.12M
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| da Silva Jorge SantosChief Executive Officer | 2.77M | – | Jul 10, 2026 | Form 4 |
| Kristian ReichChief Scientific Officer | 2.75M | – | Jul 27, 2026 | Form 4 |
| Matthias BodenstedtChief Financial Officer | 1.12M | – | Jun 22, 2026 | Form 4 |
A lower bound: it counts only the 3 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- TCAFT. Rowe Price Capital Appreciation Equity ETFWeight in the fund0.04%
- VHTVanguard Health Care Index FundWeight in the fund0.01%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.00%
3 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 133
- Q4 2025: Managers 130
- Q1 2026: Managers 148
- Q2 2026: Managers 173
Institutional investors by quarter
The fund managers holding MLTX, quarter by quarter, from Q1 2022 to Q2 2025, 14 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 173 managers held 73.41M shares, worth $1.4B. During the quarter 44 opened a position, 19 closed one, 71 added and 44 trimmed.
The largest holders, Q2 2026
- BvfIn the quarter
- Deep Track CapitalIn the quarter+9.2%
- T. Rowe Price Investment ManagementIn the quarter
- D.E. ShawIn the quarter+41%
- Cormorant Asset ManagementIn the quarter-28%
- Jupiter TopcoIn the quarter
- Logos Global ManagementIn the quarter+78%
- Weiss Asset ManagementIn the quarter+51%
- Citadel Advisors (Griffin)In the quarter+49%
- Two Sigma InvestmentsIn the quarter+53%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Bvf | 16.00M | $312M | |
| Deep Track Capital | 7.00M | +9.2% | $136M |
| T. Rowe Price Investment Management | 4.28M | $83M | |
| D.E. Shaw | 3.37M | +41% | $66M |
| Cormorant Asset Management | 3.21M | -28% | $62M |
| Jupiter Topco | 3.09M | $60M | |
| Logos Global Management | 2.68M | +78% | $52M |
| Weiss Asset Management | 2.58M | +51% | $50M |
| Citadel Advisors (Griffin) | 1.97M | +49% | $38M |
| Two Sigma Investments | 1.72M | +53% | $33M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do MoonLake Immunotherapeutics's filings show?
Who buys and sells is one part of MoonLake Immunotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have MLTX's insiders bought or sold?
From Jun 17, 2026 to Jul 29, 2026 MoonLake Immunotherapeutics's insiders bought 0 and sold $9.3M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold MLTX?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $41M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.